Mutual Advisors LLC Sells 3,917 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Mutual Advisors LLC lessened its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,156 shares of the biopharmaceutical company's stock after selling 3,917 shares during the period. Mutual Advisors LLC's holdings in Gilead Sciences were worth $1,873,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Proficio Capital Partners LLC bought a new stake in Gilead Sciences in the 4th quarter valued at about $339,000. Steward Partners Investment Advisory LLC increased its stake in Gilead Sciences by 12.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 45,818 shares of the biopharmaceutical company's stock valued at $4,232,000 after buying an additional 5,116 shares during the period. Raymond James Financial Inc. acquired a new position in Gilead Sciences during the 4th quarter valued at about $207,340,000. Finally, Lindbrook Capital LLC boosted its position in shares of Gilead Sciences by 9.6% during the 4th quarter. Lindbrook Capital LLC now owns 4,585 shares of the biopharmaceutical company's stock valued at $424,000 after purchasing an additional 403 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $275,425.00. Following the completion of the sale, the chief financial officer owned 165,110 shares in the company, valued at $18,190,168.70. The trade was a 1.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the sale, the chief executive officer owned 620,268 shares of the company's stock, valued at $68,489,992.56. This represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 58,500 shares of company stock valued at $6,340,745 over the last ninety days. 0.27% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

GILD has been the subject of several recent analyst reports. Morgan Stanley raised their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Oppenheimer lowered their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. JPMorgan Chase & Co. lifted their price target on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Needham & Company LLC reaffirmed a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Finally, Cantor Fitzgerald started coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price target for the company. Nine equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Stock Performance

GILD stock traded down $0.52 during trading hours on Tuesday, hitting $111.26. 2,954,966 shares of the stock were exchanged, compared to its average volume of 7,685,012. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 12 month low of $66.34 and a 12 month high of $119.96. The firm has a market capitalization of $138.40 billion, a P/E ratio of 23.42, a P/E/G ratio of 0.72 and a beta of 0.29. The company has a 50-day simple moving average of $107.12 and a two-hundred day simple moving average of $104.25.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the previous year, the business posted ($1.32) earnings per share. The business's revenue for the quarter was down .3% on a year-over-year basis. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were paid a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.